RaySearch Laboratories AB (publ.)(STO:RAYB) has received two orders for its RayStation® treatment planning system from the proton treatment centers Seattle ProCure Management LLC in Seattle, Washington, and Princeton ProCure Management LLC in Princeton, New Jersey. The two centers will use RayStation® for treatment planning of proton radiation therapy.
Tony Wong, Director of Physics at the Seattle ProCure Treatment Center and Dennis Mah, Director of Physics at the New Jersey ProCure Treatment Center, comment: "There are several reasons why we selected RayStation®. The most important benefits are the breadth of technology, high speed of planning and dose computation and ease of analysis compared to other modalities. This is the best system currently available in terms of robust optimization, computational accuracy and ease of use."
Marc Mlyn, President of RaySearch Americas, adds: "ProCure is a well-known name in proton therapy, and given the strong partnerships between RaySearch, IBA and now Procure, we are confident that this is a big step forward for all of us and how proton planning can evolve. We are looking forward to a long and mutually beneficial partnership with ProCure Management."
"ProCure is an organization focused on quality of care and efficient technologies. We see RaySearch as a good partner for us now and into the future, and we plan on working with them to achieve our corporate vision for improving the lives of patients with cancer by increasing access to proton therapy", says Howard Rubin, Senior Vice President of Information Systems at ProCure.
"These orders further cement our position as the leading supplier of treatment planning software for particle therapy. Together with our customers and our partner IBA, we will continue to refine our tools for proton and carbon ion therapy to fully utilize the unique technical properties of these treatment techniques to enable cancer treatments of the highest precision", says Johan Löf, CEO of RaySearch Laboratories.
The current version of RayStation® that has FDA clearance supports the proton treatment techniques Uniform Scanning and Double Scattering. Support for PBS / IMPT has been released in Europe with CE marking and 510(k) clearance in the US for PBS is expected in early 2014.